Drug name - Belrapzo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

availability in other generic markets.

Click on the highlighted region to filter.